Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for shingles nerve pain

NCT ID NCT04662281

Symptom relief Sponsor: Lexicon Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called LX9211 in 79 adults with postherpetic neuralgia, a type of nerve pain that can last for months after a shingles rash heals. The goal was to see if the drug reduces pain and helps with sleep compared to a placebo over 11 weeks. Participants had moderate to severe pain for at least 3 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

79 people

The number who actually took part.

Started

Dec 2020

Finished

Dec 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant has given written informed consent to participate in the study in accordance with local regulations * Adult male and female participants ≥18 years of age at the time of screening * Postherpetic neuralgia (PHN) pain that is present for ≥3 months after healing of herpes zoster skin rash affecting a single dermatome (Participants with more than 1 involved dermatome may also be included, provided the affected dermatomes are contiguous) * Moderate to severe pain as confirmed by average pain score using scores recorded in the pain diary in the 14 days prior to randomization Exclusion Criteria: * Presence of other painful conditions that may confound assessment or self-evaluation of PHN * History of major depressive episode, active, significant psychiatric disorders * History of clinically significant drug or alcohol use disorder * PHN affecting the face * Use of opioid medications for management of PHN within the 2 months prior to Screening Visit * Use of Non-steroidal anti-inflammatory drugs (NSAIDs) for the specific treatment of PHN pain

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postherpetic neuralgia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Neuralgia, Postherpetic postherpetic neuralgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postherpetic neuralgia

Contacts and locations

Locations

  • Lexicon Investigational Site

    Scottsdale, Arizona, 85258, United States

  • Lexicon Investigational Site

    Tucson, Arizona, 85741, United States

  • Lexicon Investigational Site

    Greenbrae, California, 94904, United States

  • Lexicon Investigational Site

    Brandon, Florida, 33511, United States

  • Lexicon Investigational Site

    Miami, Florida, 33144, United States

  • Lexicon Investigational Site

    Miami, Florida, 33174, United States

  • Lexicon Investigational Site

    Ormond Beach, Florida, 32174, United States

  • Lexicon Investigational Site

    Winter Park, Florida, 32789, United States

  • Lexicon Investigational Site

    Flossmoor, Illinois, 60422, United States

  • Lexicon Investigational Site

    Wauconda, Illinois, 60084, United States

  • Lexicon Investigational Site

    Boston, Massachusetts, 02131, United States

  • Lexicon Investigational Site

    Canton, Michigan, 48187, United States

  • Lexicon Investigational Site

    Hazelwood, Missouri, 63042, United States

  • Lexicon Investigational Site

    Albuquerque, New Mexico, 87102, United States

  • Lexicon Investigational Site

    Jenkintown, Pennsylvania, 19046, United States

  • Lexicon Investigational Site

    Baytown, Texas, 77521, United States

  • Lexicon Investigational Site

    Victoria, Texas, 77901, United States

  • Lexicon Investigational Site

    Salt Lake City, Utah, 84102, United States

  • Lexicon Investigational Site

    Kenosha, Wisconsin, 53144, United States

  • Lexicon Investigational Site (113)

    Miami, Florida, 33032, United States

  • Lexicon Investigational Site (128)

    Katowice, 40-282, Poland

  • Lexicon Investigational Site (130)

    Katowice, 640-748, Poland

  • Lexicon Investigational Site (133)

    Warsaw, 01-868, Poland

  • Lexicon Investigational Site (134)

    Lublin, 20-064, Poland

  • Lexicon Investigational Site (135)

    Prague, 16000, Czechia

  • Lexicon Investigational Site (136)

    Prague, 100 00 00, Czechia

  • Lexicon Investigational Site (137)

    Prague, 12000, Czechia

  • Lexicon Investigational Site (138)

    Choceň, 565 01, Czechia

  • Lexicon Investigational Site (140)

    Pardubice, 53002, Czechia

  • Lexicon Investigational Site (141)

    Prague, 13000, Czechia

  • Lexicon Investigational Site (147)

    Marietta, Georgia, 30060, United States

  • Lexicon Investigational Site (148)

    Cary, North Carolina, 27518, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.